[Treatment of recurrent glioblastoma with single-agent bevacizumab].
The prognosis of patients with recurrent glioblastoma is poor, as the median survival does not exceed 6 months. The aim of this study was to evaluate the efficacy of bevacizumab monotherapy in patients with recurrent glioblastoma multiforme. From April, 2012 to June, 2015, 40 patients with recurrent glioblastoma multiforme were treated with bevacizumab in a dose of 10 mg/kg every 2 weeks. The average progression-free survival was 6.4 months (2-22 months), and the 6-month progression-free survival was 42.5%. The six-month overall survival was 82.5%, which corresponds to those published in the literature. Bevacizumab monotherapy improves progression-free survival in patients with recurrent glioblastoma multiforme.